2020
DOI: 10.1080/00325481.2020.1740512
|View full text |Cite
|
Sign up to set email alerts
|

Transition of care to prevent recurrence after acute coronary syndrome: the critical role of the primary care provider and pharmacist

Abstract: Despite therapeutic advances, patients with acute coronary syndrome (ACS) are at an increased longterm risk of recurrent cardiovascular events. This risk continues to rise as the number of associated comorbidities, often observed in patients presenting with ACS, increases. Such a level of clinical complexity can lead to gaps in care and subsequently worse outcomes. Guidelines recommend providing an evidence-based post-discharge plan to prevent readmission and recurrent ACS, including cardiac rehabilitation, me… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
6
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 15 publications
(6 citation statements)
references
References 60 publications
0
6
0
Order By: Relevance
“…Furthermore, there is growing evidence from other centres in the UK and elsewhere that pharmacist-led models of post-MI medicines optimisation can improve adherence and risk factor control, and that patients appreciate the opportunity such clinics provide for discussing and resolving care-related concerns. [15][16][17][18][19][20] Our model also aligns with guidance on medicines optimisation from the UK's National Institute for Health and Care Excellence, which highlights the importance of structured review, potentially led by a pharmacist when deemed locally appropriate. 21 In addition, the upskilling of advanced clinical pharmacists to conduct these clinics in patients with complex needs fits with the concept of 'advanced pharmacy practice' advocated by leadership bodies such as the Royal Pharmaceutical Society.…”
Section: Case Discussion or Onward Referralmentioning
confidence: 97%
“…Furthermore, there is growing evidence from other centres in the UK and elsewhere that pharmacist-led models of post-MI medicines optimisation can improve adherence and risk factor control, and that patients appreciate the opportunity such clinics provide for discussing and resolving care-related concerns. [15][16][17][18][19][20] Our model also aligns with guidance on medicines optimisation from the UK's National Institute for Health and Care Excellence, which highlights the importance of structured review, potentially led by a pharmacist when deemed locally appropriate. 21 In addition, the upskilling of advanced clinical pharmacists to conduct these clinics in patients with complex needs fits with the concept of 'advanced pharmacy practice' advocated by leadership bodies such as the Royal Pharmaceutical Society.…”
Section: Case Discussion or Onward Referralmentioning
confidence: 97%
“…ACS is associated with significant morbidity and death, and older adults are at highest risk. 177 The 30-day readmission rate after ACS ranged from 11% to 14% in a meta-analysis of 14 studies. 178 Death rates vary among populations and range from 7% to 18% in the first year after STEMI.…”
Section: Transitions Cardiac Rehabilitation and Follow-upmentioning
confidence: 99%
“…On the basis of a Get With The Guidelines approach, Goldman and Harte 177 recommended that the post-ACS discharge plan address 6 elements, including (1) medications, (2) lifestyle modification/cardiac rehabilitation, (3) management of comorbidities, (4) psychosocial support, (5) socioeconomic factors, and (6) patient/family education to include teaching and preparation of patients for their own self-care (Figure 4). Polypharmacy is a frequent issue for older adults and transitions in care should include consideration of deprescribing potentially inappropriate medications and medications that are no longer needed.…”
Section: Transitions Cardiac Rehabilitation and Follow-upmentioning
confidence: 99%
“…There is an elevated long term risk of repeated cardiovascular problems in patients with ACS. As the number of related comorbidities, frequently seen in patients presenting with ACS, rises, this risk continue to increase [2]. The risk of recurrence, especially in the first year [3], is still high.…”
Section: Introductionmentioning
confidence: 99%
“…The disease, patients and health care provider centered problems can lead to these care gaps and contribute to the significant residual risk seen in ACS patients. For instance, if patients are discharge without the awareness of their illness and or their drug regimen, they may neglect to fill in their medication [2]. Patients with post hospitalized heart attack often feel insufficiently ready for the hospital to home transition [6].…”
Section: Introductionmentioning
confidence: 99%